Dr Khanani begins with the GALE study, which demonstrated that pegcetacoplan (PEG) provided benefit in visual function on a ...

Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American Society of ...

The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...

These injections deliver medication such as the new geographic atrophy drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), powerful anti-VEGFs (vascular endothelial growth factor) to keep ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan ...

The results highlighted the potential of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan ...